SOURCE: Xtalks

Xtalks Webinars

April 24, 2015 07:05 ET

How to Develop Fit-for-Purpose Quantitative IHC Assays to Enable Clinical Trial Patient Stratification, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - April 24, 2015) - Join industry expert Sharon Moulis, Director of Tissue Diagnostics Alliances at Definiens, as she discusses how quantitative image analysis can impact and inform IHC assay design to increase standardization -- from optimizing the staining protocols to overcoming inconsistent tissue collection practices. Dr. Moulis will also examine how quantitative IHC assay scoring allows for comparison of measurements across nonparallel staining runs, identifying and monitoring of sources of variability in the assay, as well as identifying mechanistically relevant cutpoints. There will be two live broadcasts on Wednesday, May 13, 2015, at 2pm BST (UK/GMT +1), and 1pm EDT.

Traditional immunohistochemistry (IHC) assays are one of the most commonly used diagnostic assays because they are easily deployed and cost effective. However, IHC assays do pose significant challenges to companion diagnostic and patient stratification use in regards to their lack of standardization and reliability as well as producing qualitative, and not quantitative, results. Due to these challenges, there has been limited success of an IHC assay becoming a companion diagnostic. However, IHC assays have great promise as a powerful and robust diagnostic tool that could be used to stratify patients for clinical trials and ultimately demonstrate the medical value of important cancer therapies.

This webinar will go into detail on how to devise a method of quantitative IHC assay design that overcomes the inherent challenges of traditional IHC assays. With quantitative IHC assays, clinical researchers can increase the chance of finding the optimal cutpoint of biomarker expression and maximizing the chance of success for the IHC assay in companion diagnostic use. Attendees will learn how, through use of standard curves and quantitative image analysis, the required target expression level can be determined and IHC assays re-optimized for more uniform and consistent scoring by a pathologist.

To learn more about this event visit: How to Develop Fit-for-Purpose Quantitative IHC Assays to Enable Clinical Trial Patient Stratification

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/4/23/11G039361/Images/small_logo-740736732461.jpg

Contact Information